Dr. Brian King was appointed Director of the Food and Drug Administration’s Center for Tobacco Products (CTP) in July 2022. In this position, Dr. King is responsible for assuring that CTP accomplishes its public health goals and for operationalizing the Center’s vision and mission as it implements the Family Smoking Prevention and Tobacco Control Act.
Dr. King has worked for nearly two decades to provide sound scientific evidence to inform tobacco control policy and to effectively communicate this information to key stakeholders, including decision makers, the media, and the general public. Prior to joining FDA, he served as the Deputy Director for Research Translation in CDC’s Office on Smoking and Health, and more recently as the Executive Editor of CDC’s Morbidity & Mortality Weekly Report Series. He has authored more than 200 scientific journal articles related to tobacco prevention and control, served as Senior Associate Editor for multiple U.S. Surgeon General’s Reports on tobacco, and was lead author of CDC’s 2014 evidence-based guide, “Best Practices for Comprehensive Tobacco Control Programs.”
Dr. King holds a Ph.D. and M.P.H. in Epidemiology from the State University of New York at Buffalo.
Tobacco product use is the leading cause of disease, disability, and death in the United States. The risks of tobacco product use have been compounded by the COVID-19 pandemic, with emerging data showing that current and former cigarette smokers are at increased risk of more severe illness from COVID-19. In this webinar, participants will gain an understanding of the state of the science with regard to COVID-19 outcomes and tobacco product use, including cigarette smoking and e-cigarette use. The speaker will also provide participants with information about evidence-based strategies to prevent and reduce tobacco product use, including resources for healthcare providers and the general public.
At the end of the webinar, you will be able to:
- Describe the adverse health effects of tobacco product use in the United States, as well as disparities in use across population groups.
- Discuss the state of the science with regard to COVID-19 outcomes and tobacco product use, including cigarette smoking and e-cigarette use.
- Explain clinical and public health approaches to prevent and reduce tobacco product use, including during the COVID-19 pandemic.
CME/CEU registration is no longer available for this recorded activity. The accreditation has expired for this course.
Certificates of Attendance
Click here to generate a certificate of attendance for participating on this webinar.